Mylab Discovery Solutions Private Limited

June 10, 2026

Facilities	Amount (₹ crore)	Rating[1]	Rating Action
Long Term Bank Facilities	360.00	CARE B+; Stable; ISSUER NOT COOPERATING*	Rating continues to remain under ISSUER NOT COOPERATING category and Downgraded from CARE BB-; Stable

Details of instruments/facilities in Annexure-1.
*Issuer did not cooperate; based on best available information.
The list of facilities / instruments falling under the purview of various financial sector regulators (FSRs), along with the names of respective FSRs has been disclosed under Annexure 6.

Rationale and key rating drivers

CARE Ratings Limited (CareEdge Ratings) had vide its press release dated May 14, 2025, placed the ratings of Mylab Discovery Solutions Private Limited (Mylab) under the 'issuer non-cooperating' category as Mylab had failed to provide information for monitoring of the rating as agreed in its Rating Agreement. Mylab continues to be non-cooperative despite repeated requests for submission of information through e-mails between March 2026 to May 2026 and phone calls. In line with the extant SEBI guidelines, CareEdge Ratings has reviewed the rating on the basis of the best available information which however, in CareEdge Ratings opinion is not sufficient to arrive at a fair rating.

Users of this rating (including investors, lenders and the public at large) are hence requested to exercise caution while using the above rating.
The rating is revised on account of non-availability of requisite information due to non-cooperation by Mylab with CareEdge Ratings' effort to undertake a review of the outstanding rating as CareEdge Ratings views information availability risk as key factor in its assessment of credit risk profile.

Analytical approach: Standalone; factoring operational linkages in the form of technical support extended by the Poonawalla group which also currently holds 42.50% stake in Mylab.

Outlook: Stable
The stable outlook reflects that the rated entity is likely to improve its financial performance and will receive need-based support from the Poonawalla group.

Detailed description of key rating drivers:

At the time of rating on June 26, 2023, the following were the rating strengths and weaknesses (updated for the information available from Registrar of Companies)

Key weaknesses

Delay in execution of TB campaign and related uncertainties: While Government of India (GoI) has a target to eliminate tuberculosis (TB) by 2025, the TB eradication campaign is yet to see the full fledge implementation. There has been delay in the overall execution of the programme, which has negatively impacted the overall performance of the company. The company has envisaged revenue from TB segment to start from FY23; however, as informed by the management, the same has not taken place. The progress and implementation of TB campaign is expected to have direct impact on the overall performance of the company and the same will remain a key monitorable.

Limited track record of operation, moderate revenue and weak capital structure: Mylab has limited track record of operations and the company's total income had been at moderate levels and stood at ~₹143 crores in FY24 compared to ~₹ 94 crores in FY23. Further, its profit before interest, lease rentals, depreciation, and taxation (PBILDT) stood at ~ ₹60 crores during FY24.The capital structure continues to remain weak, with gearing increasing to 3.16x as on March 31, 2024, from 2.48x as on March 31, 2023, primarily due to an increase in total debt to ₹485 crore in FY24 from ₹375 crore in FY23.

Elongated working capital cycle: Mylab's working capital cycle remained elongated and stood at around 439 days (PY: 383 days) during FY24. The average collection days of the company stood at around 325 days (PY:304 days) during FY24. The company's average inventory days also has remained high at around 326 days (PY:188 days) during FY24 due to stocking up. The company's working capital cycle thus remains elongated on account of the debtors being stuck with government bodies, stocking up of the inventories and procuring required raw material by paying advance.

[1]Complete definition of ratings assigned are available at www.careratings.com and other CARE Ratings Limited's publications.

Key strengths

Experienced promoters coupled with association with Poonawalla group: Mylab is a molecular diagnostic company which develops and commercialises diagnostic kits used in human diagnostics, food safety, agriculture, and veterinary medicines. It was incorporated by Hasmukh Rawal and Shailendra Kawade. Hasmukh Rawal is a biotechnologist-turned-entrepreneur who has rich experience in the commercial development of applied molecular diagnostics solutions. Shailendra Kawade is the Co-founder and Chairman of the Board at Mylab. He has more than 15 years of experience in the life science industry. Mylab uses science and technology to simplify the nature of disease detection and help labs in obtaining timely, reliable, and actionable results. It offers a broad range CE-IVD marked real-time PCR kits with ISO13485 manufacturing standards.

Dr Cyrus Poonawalla, the promoter of SIIPL holds 10% stake in Mylab in personal capacity and 32.50% is held by the Poonawalla group company- Rising Sun Holdings Private Limited (RSHPL), which is owned and controlled by Adar Poonawalla. Mylab has several years of experience in manufacturing real-time reverse transcription–polymerase chain reaction (RTPCR) kits. It manufactures a range of kits at the facility approved by Central Drugs Standard Control Organization (CDSCO) and is compliant with MDR 2017 regulation for manufacturing medical devices of Class C and D. Mylab currently manufactures ID-NAT screening kits for blood banks/hospitals, kits for testing human ailments like HIV, HBV, HCV, Covid -19, tuberculosis, cancer, genetic disorder and diseases caused by parasitic, viral, and bacterial infection.

Tripartite agreement with Indian Council of Medical Research (ICMR) and Serum Institute of India Private Limited (SIIPL) for end-to end TB solution: Mylab had entered into a tripartite agreement with ICMR and SIIPL wherein Mylab will be providing end-to-end TB solution to ICMR. SIIPL has developed a vaccine for TB (rBCG) along with a skin TB test (CY-TB), the exclusive marketing and distribution rights of the same for the entire world is with Mylab. This apart, Mylab has manufactured its own TB detection kit. As per the agreement, Mylab will be providing ICMR its own TB diagnostic kit along with vaccine. With very limited players in TB testing tool kit market, Mylab has better prospects to leverage on the opportunity. The other players offer only TB testing kit, whereas Mylab has complete TB solution which includes administering of vaccine. This apart, the company is also in discussion for empanelling pharma companies to supply medicine for TB.

Liquidity: Stretched

With the deterioration of the overall performance the liquidity position of the company remains stretched. In the past, to support the operations of the company, the promoters have infused interest free unsecured loans to the extent of ₹145 crore. As on March 31, 2023, unsecured loans to the tune of ₹143.50 crore from the promoters remain outstanding. Further, as on March 31, 2023 company has outstanding loans of ₹ 100 crore from SIIPL. During FY23, company generated negative cash accruals of ~40 crore.

Assumptions/Covenants: Not applicable

Environment, social, and governance (ESG) risks: Not applicable

Applicable criteria

Information Adequacy Risk and Issuer Non-Cooperation
Definition of Default
Rating Outlook and Rating Watch
Manufacturing Companies
Liquidity Analysis of Non-financial sector entities
Financial Ratios – Non financial Sector

About the company and industry

Industry classification

Macroeconomic indicator	Sector	Industry	Basic industry
Healthcare	Healthcare	Healthcare Equipment & Supplies	Medical Equipment & Supplies

Mylab is a molecular diagnostic company which develops and commercialises diagnostic kits used in human diagnostics, food safety, agriculture, and veterinary medicines. It offers a cost-effective diagnostic solution for the early detection and monitoring of a wide range of human ailments. The company offers diagnostic solution for diseases like COVID-19, tuberculosis, cancer, genetic disorder and for diseases caused by parasitic, viral, bacterial infection.

Brief Financials (₹ crore)	March 31, 2023 (A)	March 31, 2024 (A)
Total operating income	94.27	142.91
PBILDT*	-53.76	60.43
Profit after tax (PAT)	-42.41	1.66
Overall gearing (x)	2.48	3.16
Interest coverage (x)	-3.55	1.70

A: Audited; Note: these are latest available financial results
*PBILDT: Profit before interest, lease rentals, depreciation and tax

Status of non-cooperation with previous CRA: Not applicable

Any other information: Not applicable

Rating history for last three years: Annexure-2

Detailed explanation of covenants of rated instrument / facility: Annexure-3

Complexity level of instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned and Rating Outlook
Fund-based - LT-Term Loan		-	-	31/08/2028	122.00	CARE B+; Stable; ISSUER NOT COOPERATING*
Fund-based - LT-Working Capital Limits		-	-	-	238.00	CARE B+; Stable; ISSUER NOT COOPERATING*

*Issuer did not cooperate; based on best available information.

Annexure-2: Rating history for last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2026-2027	Date(s) and Rating(s) assigned in 2025-2026	Date(s) and Rating(s) assigned in 2024-2025	Date(s) and Rating(s) assigned in 2023-2024
1	Fund-based - LT-Working Capital Limits	LT	238.00	CARE B+; Stable; ISSUER NOT COOPERATING*	-	1)CARE BB-; Stable; ISSUER NOT COOPERATING* (14-May-25)	-	1)CARE BB+; Stable; ISSUER NOT COOPERATING* (28-Feb-24) 2)CARE A-; Stable (26-Jun-23)
2	Fund-based - LT-Working Capital Demand loan	LT	-	-	-	-	-	1)Withdrawn (26-Jun-23)
3	Fund-based - LT-Bank Overdraft	LT	-	-	-	-	-	1)Withdrawn (26-Jun-23)
4	Fund-based - LT-Bill Discounting/ Bills Purchasing	LT	-	-	-	-	-	1)Withdrawn (26-Jun-23)
5	Fund-based - LT-Term Loan	LT	122.00	CARE B+; Stable; ISSUER NOT COOPERATING*	-	1)CARE BB-; Stable; ISSUER NOT COOPERATING* (14-May-25)	-	1)CARE BB+; Stable; ISSUER NOT COOPERATING* (28-Feb-24) 2)CARE A-; Stable (26-Jun-23)

*Issuer did not cooperate; based on best available information.
LT: Long term;

Annexure-3: Detailed explanation of covenants of rated instruments/facilities: Not applicable

Annexure-4: Complexity level of instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Fund-based - LT-Term Loan	Simple
2	Fund-based - LT-Working Capital Limits	Simple

Annexure-5: Lender details

To view lender-wise details of bank facilities please click here

Annexure-6: List of Facilities/Instruments and FSRs

As required by SEBI Circular dated February 10, 2026 to Credit Rating Agencies (CRAs), the list of activities or instruments falling under the purview of various FSRs, along with the names of respective FSRs, is being disclosed below:

Sr. No.	Facilities/Instruments Name	Regulator of the Instruments[2]
1.	Listed / Proposed to be Listed Bonds / Debentures / Preference Shares (All Securities)	SEBI
2.	Unlisted / Proposed to be Unlisted Bonds / Debentures / Preference Shares (All Securities)	MCA
3.	Listed PTCs / Securitisation Notes (Originated by Entities Regulated by RBI) *	SEBI
4.	Listed PTCs / Securitisation Notes (Originated by Entities Not Regulated by RBI) *	SEBI
5.	Unlisted PTCs / Securitisation Notes (Originated by Entities Regulated by RBI) *	RBI
6.	Listed Commercial Paper and NCDs with Original Maturity Less Than 1 Year	RBI
7.	Unlisted Commercial Paper and NCDs with Original Maturity Less Than 1 Year	RBI
8.	Loan Facilities (Fund / Non-Fund Based) From Banks / NBFCs / NHB / FIs ^	RBI
9.	External Commercial Borrowings and Other Similar Borrowings	RBI
10.	Certificates of Deposit	RBI
11.	Fixed Deposits Raised by Banks, NBFCs, HFCs, FIs	RBI
12.	Fixed Deposits Raised by Corporates Other Than Banks, NBFCs, HFCs, FIs	MCA
13.	Inter Corporate Deposits / Loans Extended by Corporates	MCA
14.	Borrowing Programme ~	-
15.	Issuer Ratings #	-
16.	Credit Ratings for Capital Protection Oriented Schemes (By Mutal Funds and AIFs)	SEBI
17.	Credit Quality Ratings (CQRs) for Mutual Fund Schemes and Schemes of AIFs	SEBI
18.	Listed Security Receipts	SEBI
19.	Unlisted Security Receipts	RBI
20.	Independent Credit Evaluation (ICE)	RBI
21.	Expected Loss Ratings (For Loan Facilities (Fund / Non-Fund Based) from Banks / NBFCs / NHB / FIs)	RBI
22.	Expected Loss Ratings (Listed / Proposed to be Listed Bonds / Debentures / Preference Shares (All Securities))	SEBI
23.	Expected Loss Ratings (Unlisted / Proposed to be Unlisted Bonds / Debentures / Preference Shares (All Securities))	MCA
24.	Unlisted PTCs / Securitisation Notes (Originated by Entities Not Regulated by RBI) *	Investor-side regulator such as IRDAI, PFRDA @

* Includes securitisation transactions involving assignee payout, acquirer's payout.

~ The rated instrument may involve issuance of different instruments such as debt securities (listed or otherwise), bank loans, commercial paper (listed or otherwise), etc. The regulator of the instrument may accordingly be SEBI, RBI or MCA and can only be determined upon issuance. In the rating notes subsequent to issuance(s), CARE Ratings Limited shall separately capture the rated quantum details along with names of respective regulators.

^ Includes bank facilities such as liquidity facility, second loss facility that are part of securitisation transactions.

There is no instrument being rated and hence, Regulator of the Instrument is not applicable. The rating scale and definitions are being followed as stipulated in SEBI Master Circular for CRAs.

@ These ratings were assigned during regulatory regime prior to introduction of SEBI CRA Circular dated February 10, 2026 and the investor side regulators have accordingly been included.

Note: For facilities / instruments falling under the purview of FSRs other than SEBI, the grievance / dispute redressal mechanisms and investor protection mechanisms provided by SEBI shall not be available.

Note on complexity levels of rated instruments: CareEdge Ratings has classified instruments rated by it based on complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for clarifications.

[2]SEBI: Securities and Exchange Board of India; RBI: Reserve Bank of India; MCA: Ministry of Corporate Affairs; IRDAI: Insurance Regulatory and Development Authority of India; PFRDA: Pension Fund Regulatory and Development Authority

Contact us

Media Contact	Analytical Contacts
Mradul Mishra Director **CARE Ratings Limited** Phone: +91-22-6754 3596 E-mail: mradul.mishra@careedge.in **Relationship Contact** Pradeep Kumar V Senior Director **CARE Ratings Limited** Phone: 044-28501001 E-mail: pradeep.kumar@careedge.in	Pulkit Agarwal Director **CARE Ratings Limited** Phone: 912267543505 E-mail: pulkit.agarwal@careedge.in Pritesh Rathi Associate Director **CARE Ratings Limited** Phone: 91-20-4000 9000 E-mail: Pritesh.Rathi@careedge.in Uday Karupothula Lead Analyst **CARE Ratings Limited** E-mail: Uday.karupothula@careedge.in

About us:
Established in 1993, CareEdge Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the Reserve Bank of India. With an equitable position in the Indian capital market, CareEdge Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CareEdge Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CareEdge Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit. For more information: www.careratings.com

Privacy Policy applies. For Privacy Policy please refer to https://www.careratings.com/privacy_policy

**For detailed Rating Report and subscription information,
please visit www.careratings.com**